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Abstract: 
BACKGROUND: Gestational diabetes mellitus (GDM) is diabetes that is diagnosed for the first 
time during pregnancy. Rates of GDM in the U.S. and internationally have been rising in recent 
years. GDM is associated with an increased risk of adverse pregnancy outcomes, an increased 
risk of maternal Type 2 Diabetes Mellitus in the future, and an increased risk of future chronic 
disease for the neonate. Although recommendations differ, most guidelines recommend 
screening women with an oral glucose tolerance test during the second trimester of pregnancy 
and advise earlier screening in women considered high-risk for developing GDM.  
AIMS: The objective of this systematic review will be to evaluate the accuracy of various 
methods of early screening for GDM as compared with traditional screening during the second 
trimester, and to determine whether earlier screening leads to improved maternal- fetal health 
outcomes.  
METHODS: PubMed and the Cochrane Library were systematically searched according to pre-
established eligibility criteria. Hand searches of relevant references and the grey literature were 
also done. One reviewer examined abstracts for eligibility and abstracted relevant data from 
included articles. Each included articles was assessed for quality.  
RESULTS: Data on the accuracy and predictive ability of early screening was mixed. Early 
screening was done most often using fasting plasma glucose, however cutoff values that 
predicted gestational diabetes varied widely. Oral glucose tolerance testing and glycosylated 
hemoglobin were used infrequently as an early screening test. Though the data were also mixed 
on pregnancy outcomes associated with early screening, no outcomes were consistently shown to 
be improved through the process of early screening.  
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CONCLUSIONS: Due to heterogeneity of methods and inconsistent outcomes with early 
gestational diabetes screening, no method may conclusively be put forth as a superior method of 
screening for gestational diabetes early in pregnancy. Additionally, at this point, early screening 
overall cannot be justified due to a lack of evidence of improvement in maternal and neonatal 
outcomes. Future research should include better study designs, with more attention paid to 
clinically significant outcomes for women and their babies.  
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Introduction: 
Defining Gestational Diabetes Mellitus: Physiologic changes to metabolism and the 
endocrine system take place during pregnancy to support the growth and development of the 
fetus. Resistance to insulin [similar to that seen in Type 2 Diabetes Mellitus (T2DM)] is often 
seen during the second and third trimesters of pregnancy. If the woman’s pancreas is unable to 
compensate for this rising resistance by increasing the secretion of insulin, then blood glucose 
levels will begin to rise which may increase risk of adverse birth outcomes.3 Increased risk of 
adverse maternal- fetal outcomes has been shown to have a linear relationship to elevated levels 
of plasma glucose. Therefore, any elevation in blood glucose levels above what is considered 
normal may increase a woman's risk of negative birth outcomes, whether or not the levels were 
high enough to qualify as GDM.30 Gestational diabetes mellitus (GDM) is defined by the 
American Congress of Obstetricians and Gynecologists (ACOG) as glucose intolerance, which is 
recognized for the first time during pregnancy. This often includes both women who have 
previously undiagnosed T2DM as well as those who develop diabetes mellitus for the first time 
during pregnancy.34 Most women diagnosed prior to 24 weeks of gestation are thought to have 
had pre-gestational T2DM. Approximately 6-8% of pregnancies in the United States are 
complicated by GDM, with an even higher rate in obese patients (up to 14%).19 Internationally, 
rates of GDM are rising as well, closely paralleling the growing prevalence of mothers with 
advanced maternal age, obesity, and T2DM.33  
Gestational Diabetes and Associated Risks: Pregnant women with GDM have been 
shown to experience increased risks of Cesarean delivery (odds ratio 1.88), stillbirth (odds ratio 
2.00), and preeclampsia (odds ratio 1.61).27 Resulting offspring are over three times more likely 
to be large for gestational age (LGA) and may be up to four times as likely to experience birth 
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injury, respiratory, cardiac and congenital disorders.34 Women with GDM are also more likely to 
experience a shoulder dystocia during delivery (odds ratio 4.07).20 Women who are diagnosed 
with GDM have a significantly increased risk of developing T2DM (odds ratio 3-7).8, 18 Children 
born to mothers with GDM may have increased rates of obesity and T2DM in the future.12  
Screening for Gestational Diabetes Mellitus: There are significant variations in screening 
guidelines as well as thresholds used to define GDM across international organizations. While 
recommendations differ between professional societies, most recommend universal screening of 
asymptomatic women between 24-28 weeks gestation, and earlier screening (before 20 weeks 
gestation) in high-risk women. Early screening is used in addition to second trimester screening 
and is hoped to lead to earlier identification and treatment of diabetes in pregnancy leading to 
better health outcomes. Risk factors for GDM include: advanced maternal age, increasing parity, 
ethnicity (e.g. Hispanic and African American populations), obesity, high gestational weight 
gain, physical inactivity, low-fiber high-glycemic- load diets, history of previous macrosomia or 
GDM, family history of T2DM, and history of polycystic ovarian syndrome (PCOS).9, 26, 32 
According to ACOG’s 2001 guidelines, women with low risk of GDM may forego testing. This 
requires women to be under 25 years of age, not a member of a high risk ethnic group, BMI ≤ 
25, have no history of abnormal glucose tolerance or macrosomia, and have no first-degree 
relatives with diabetes. However, only about 10% of pregnant women meet these criteria. 
Therefore, many physicians choose to screen all pregnant women.1 
 In the United States, the oral glucose tolerance test (OGTT) is considered to be the gold 
standard for diagnosis of gestational diabetes mellitus by ACOG and the United Stated 
Preventive Services Task Force (USPSTF). This tool has been shown to be more predictive of 
adverse pregnancy outcomes than other diabetes screening tools used in pregnancy, likely due to 
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the fact that GDM is primarily a post-prandial condition.25 However, OGTT testing is expensive, 
unpleasant, and not well tolerated by some patients, especially those experiencing pregnancy 
related nausea.3 Other organizations, such as the International Association of Diabetes in 
Pregnancy Study Group (IADPSG) and the American Diabetes Association (ADA) have recently 
begun to advocate for the use of Glycosylated Hemoglobin (HbA1c) levels for use in screening 
during pregnancy.28 The IADPSG, ADA, and World Health Organization (WHO) recommend 
screening for diabetes at the first antenatal visit using an HbA1c value of ≥ 6.5% as a diagnostic 
cut point,22, 35 however this recommendation is based on data collected in non-pregnant patients.  
Some studies have shown that a reference interval of 4.3-5.4% should be used as normal values 
for A1C in pregnant women, while values between 5.7-6.4% are associated with impaired 
glucose tolerance and an increased risk (12-25%) of developing T2DM over the first ten years 
postpartum.2, 21 
The most current recommendations by ACOG suggest using a two-step diagnostic 
approach with a 50-g, 1-hour OGTT between 24-28 weeks for screening, and follow-up testing 
using a 100-g, 3-hour diagnostic OGTT for all positive screens. Women with GDM are 
subsequently tested for continued diabetes at 6-12 weeks postpartum.1 For many years the 
IADPSG has recommended a one-step approach to establishing a diagnosis. This includes a 75-
g, 2-hour test done in the second trimester with a positive defined as any single threshold value 
met or exceeded (fasting value: 92 mg/dL; 1-hr: 180 mg/dL; or 2-hr: 153 mg/dL).22 Some studies 
have demonstrated that, using IADPSG guidelines, universal screening using a 2-hour oral 
glucose tolerance test for GDM is marginally cost effective. Therefore, the cost of screening all 
women in the second trimester and treating those who test positive, is outweighed by the costs 
saved on complications associated with GDM (such as cesarean delivery, NICU admissions, etc.) 
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One study concluded that if cost of treatment for GDM is < $2630 and treatment is at least 
74.9% effective at preventing complications associated with GDM, then the ICER was 
$61,503.23 The ADA recommends screening for undiagnosed T2DM at first prenatal visit using a 
fasting value of 110-125mg/dL  as a positive test, instead of > 92 mg/dL.37 Increasingly since the 
early twentieth century, there has been a push toward international standardization of definitions 
and guidelines based on outcomes from the Hyperglycaemia and Adverse Pregnancy Outcome 
(HAPO) study.12  
The HAPO study was a landmark study done in 2002 which aimed to set international 
diagnostic criteria for threshold values based on the predictive value for adverse pregnancy 
outcomes. This trial was done in approximately 25,000 women over five years and looked at 
birth outcomes such as cesarean delivery, increased fetal size (macrosomia/LGA/obesity), 
neonatal morbidity (hypoglycemia), and fetal hyperinsulinism. The study concluded that 
increased glycemic levels were related to increasing risk of adverse fetal outcomes. The IADPSG 
used the data from this study to create their recommendations for international screening 
guidelines.  
Justification for a Systematic Review: Some organizations and practitioners have begun 
to investigate the utility of first trimester screening for GDM. The rationale behind this is that 
earlier detection and treatment of diabetes (either pre-gestational or gestational) may allow better 
glucose control throughout pregnancy, leading to better birth outcomes.5 In order to justify 
implementing a new screening test, most experts recommend that an effective treatment must 
exist for patients identified through early screening, and there must be evidence that this early 
treatment leads to better outcomes.29 Therefore, in order for researchers and clinicians to 
advocate for early GDM screening, there must be data supporting better health outcomes for 
9 
those women (and their children) who are screened at an earlier time period. This review will 
systematically search the recent literature to (1) understand the accuracy of early screening 
techniques and relevant threshold values among pregnant women, as contrasted to second 
trimester screening, in predicting or diagnosing pre-gestational or gestational diabetes mellitus, 
and (2) to explore the benefits and/or harms of first trimester screening versus second trimester 
screening and its relationship to birth outcomes (such as LGA, macrosomia, shoulder dystocia, 
and stillbirth). 
  
Methods: 
Two key questions (KQs) were posed for investigation by this review:  
  KQ1. Are the available tests accurate in early pregnancy and what cutoff values 
should be used?  
  KQ2. Does first trimester screening lead to better birth outcomes for mother and fetus 
than second trimester screening? 
 
Search Strategy: No previous review protocol has been established for a review of these 
specific questions of interest. Therefore, methods for this review were formulated by the author 
using the PRISMA guidelines for performing and reporting systematic reviews. Databases 
searched include PubMed and the Cochrane Library from 2002 through June, 1 2016; the full 
search strategies are shown in Appendix 1. To identify unpublished (grey) literature, I also 
searched clinicaltrials.gov records and conducted hand-searches of key articles identified through 
database searches. The start date of 2002 was chosen for the database searches because another 
similar (but outdated), systematic review on screening for GDM was published at that time and 
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included literature searches through 2002.29 That review concluded that evidence up to that point 
was limited and insufficient to justify early screening.  
Inclusion/Exclusion Criteria: Inclusion and exclusion criteria of articles eligible for 
inclusion were broadly defined (Table 1). Study types included for analysis were randomized 
trials, previously published systematic reviews, and observational studies assessing the accuracy 
of first trimester screening compared to second trimester screening, or assessing the health 
benefits (maternal or child birth outcomes) resulting from earlier screening were included. The 
population of interest was pregnant women with no previous diagnosis of T1DM or T2DM. This 
includes studies investigating early screening in both low and high-risk populations. Articles 
were excluded if the study population was women with concurrent medical conditions (e.g. 
thyroid disease, Addison’s disease, etc.) Studies were included from both developed and 
developing countries in order to assess and expand the external validity of the conclusions of this 
review. Due to the wide variety of current guidelines and criteria, studies were not excluded 
based on their definition of GDM. Studies were only included if the full text could be found in 
English. Additionally, articles were excluded if they did not contain original research (i.e. study 
protocols or responses to published articles) or did not investigate the interventions, controls, and 
outcomes of interest. Due to the limited amount of available literature on the established 
interventions and outcomes, the author felt that these broad eligibility criteria were appropriate in 
order to obtain a more inclusive understanding on the existing literature (see Table 1 for full 
inclusion and exclusion criteria). 
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Table 1: Eligibility Criteria - full inclusion/exclusion criteria for studies in systematic review. 
 Inclusion Exclusion 
Population Pregnant women without a prior DM 
diagnosis (both low and high-risk 
populations), singleton pregnancies, 
and no concurrent medical conditions 
Women with pre-gestational 
diabetes, multiple gestation 
pregnancies, concurrent medical 
conditions 
Screening 
Intervention 
Early glucose screening at or before 
20 weeks gestation using any of the 
following methods: fasting plasma 
glucose, oral glucose tolerance 
testing, or HbA1C. 
All other tests 
Comparator Second trimester screening between 
24-28 weeks gestation by gold 
standard (oral glucose tolerance test) 
All other comparators 
Outcomes KQ1: Diagnosis of GDM.  
 
KQ 2: Birth outcomes: preterm birth, 
C-section, LGA, shoulder dystocia, 
preeclampsia, macrosomia, stillbirth 
All other outcomes 
Timing of 
Literature 
Review 
January 2002 to June 2016 Articles published before 2002 
Outcome 
Timing 
Participants identified in first 
trimester followed through birth 
Participants did not present to 
provider or were not included in 
study in first trimester 
Study Designs Randomized controlled trials, 
observational cohort studies 
(retrospective and prospective), and 
systematic reviews 
Non-systematic review, in-progress 
trials with no published results, 
case studies, case series 
Language Article available in English Full article not available in English 
(only abstract available in English) 
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Study Selection: Articles identified by the database searches were exported into RefWorks 
for removal of duplicates. Those identified through ClinicalTrials.gov were assessed without 
exportation. A Microsoft Excel spreadsheet was used to track articles and for manual de-
duplication of any duplicates missed by the RefWorks program. All abstracts were reviewed by 
one reviewer for their compatibility with the established inclusion and exclusion criteria. Full 
article PDFs were obtained for those articles deemed eligible by their abstracts for inclusion in 
this review. These full articles were subsequently assessed by the author for eligibility again 
based on inclusion and exclusion criteria. Those found to be relevant to one or both of the two 
key questions were included for final review (citations and reasons for exclusion are included in 
Figure 1). Peer-reviewed publications and organizational and national guidelines were the 
preferred sources of data. Non-published and in-progress trials which did not have available 
results were excluded.  
Synthesis of Evidence: Studies included in the final systematic review were critically 
appraised by one reviewer for risk of bias at the study level (i.e. selection bias, measurement 
bias, and confounding). Critical appraisal was done using the USPSTF Quality Rating Criteria 
(See Appendix 2 for USPSTF Quality Rating Criteria). A narrative summary of articles meeting 
inclusion criteria was synthesized for a qualitative investigation of the status of current literature 
and recommendations.  
Due to a limited number of heterogeneous studies meeting inclusion criteria and 
addressing one of the two KQs, no meta-analysis was performed. In addition to internal validity 
within included studies, external validity (i.e. applicability) of included studies was also 
assessed.  
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Figure 1. Article Flow Diagram.  
 
Results: 
Study Selection: Searches of PubMed, the Cochrane Library, and grey literature returned 
536 search results, which were eligible for abstract screening. None of clinical trials.gov 
abstracts found had reported results, and therefore all of these trials (n = 7) were excluded. After 
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abstract review, 85 references underwent full-text review. Fourteen articles were included in the 
final evidence synthesis (see Figure 1 for full flow diagram of article inclusion and exclusion).  
Study Characteristics: Of these 14 studies, none were randomized controlled trials; two 
were systematic reviews and all others were cohort studies (both retrospective and prospective). 
The majority of studies were conducted in developed countries, however three were from 
developing countries (i.e. India, Pakistan, and China).31, 34, 37  
Of the 14 included studies, nine addressed KQ1. Included strategies of first trimester 
screening were: fasting plasma glucose (6 studies), oral glucose tolerance tests (1 study), and 
glycosylated hemoglobin (2 studies). All studies enrolled women early in pregnancy prior to the 
time of traditional GDM screening (24-28 weeks gestation). Those women who tested within 
normal limits on the first screening test were then retested using OGTT between 24-28 weeks 
gestation as the gold standard. Of these nine studies, four were rated as good quality while the 
rest were judged to be of fair to poor quality. 
Seven of the included studies examined birth outcomes in relation to early GDM 
screening and were therefore relevant to answering KQ2. The pregnancy outcomes most 
commonly reported across trials were preterm birth, preeclampsia, cesarean delivery, large for 
gestational age infant/macrosomia, shoulder dystocia, neonatal complications, and stillbirth. 
While some studies investigated only one of these outcomes (i.e. stillbirth)34 each of these 
outcomes was addressed by multiple trials. The results and qualities of these studies varied 
widely. Three studies were rated as good quality, the rest were rated as fair to poor; common 
sources of bias across all studies included high risk of selection bias and no control for 
confounding factors (see Table 2 for study characteristics; Table 5 for individual sources of bias 
by study).  
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Table 2. Study characteristics of each study. 
Study, 
Year 
Study 
Design 
Country Sample 
Size 
High risk vs 
random POI** 
Study Period Key 
Question 
Alunni, 
20154 
Retrospect
ive cohort 
study 
USA 1298 NR* July 2010 - 
June 2012 
KQ2 
Bito, 20056 Prospectiv
e 
observatio
nal study 
Hungary 155 High Risk 
 
Jan 1, 2001 - 
Sept 30, 2002 
KQ1 
Corrado, 
20127 
Retrospect
ive cohort 
study 
Italy 738 Random 
 
May 2010 - 
May 2011 
KQ1 
Fong, 
201410 
Retrospect
ive cohort 
study 
USA 526 NR* Jan 2011 - 
Jan 2013 
KQ1; 
KQ2 
Gandhi, 
201111 
Retrospect
ive cohort 
study 
UK 190 High Risk 
 
Jan 2009 - 
Feb 2011 
KQ1 
Harrison, 
201513 
Prospectiv
e cohort 
study - as 
part of 
larger 
RCT 
Australia 224 High Risk 
 
2008-2010 KQ1 
Hawkins, 
200814 
Retrospect
ive cohort 
study 
USA 2257 High Risk 
 
Dec 1999 - 
Jun 2005 
KQ2 
16 
Hivert, 
201215 
Retrospect
ive cohort 
study 
Canada 7839 High Risk 
 
2004-2005; 
2006-2007; 
2008-2009 
KQ2 
Hughes, 
201416 
Prospectiv
e cohort 
study 
New 
Zealand 
974 Random 2008-2010 KQ1; 
KQ2 
Most, 
200924 
Retrospect
ive cohort 
study 
USA 340 Random 2003-2007 KQ2 
Scott, 
200229 
Systemati
c review 
UK 135 
studies 
High Risk 
 
All literature 
through 2000 
KQ1; 
KQ2 
Seshiah, 
200731 
Prospectiv
e cohort 
study 
India 739 Random NR KQ1 
Syed, 
201134 
Systemati
c review 
Study 
done in 
Pakistan; 
searched 
literature 
from all 
countries 
70 
articles 
include
d (14 
interven
tion, 56 
observa
tional) 
NR* Literature up 
to 2010 
KQ2 
Zhu, 201337 Retrospect
ive cohort 
study 
China 14039 Random Jan 1, 2010 - 
Feb 29, 2012 
KQ1 
 
*NR: Not reported 
**POI: Population of Interest 
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KQ1: Accuracy and Predictive Ability of First Trimester Screening  
Three methods of early GDM screening were used across the included literature. First 
trimester fasting plasma glucose (FPG) was used most commonly (6 studies) with proposed 
threshold values ranging from 4.7 mmol/L to 5.6 mmol/L. One study supported the IADPSG 
threshold of ≥ 5.1 mmol/L, three studies that found evidence for lower threshold values, and only 
one study advocated for higher threshold values. One study investigated the accuracy of OGTT 
at the first antenatal visit. Lastly, two included studies evaluated the predictive ability of early 
hemoglobin A1c (HbA1c) screening (See Table 3 for a summary of studies addressing KQ1).10, 
16 
First Trimester Fasting Plasma Glucose: Six of the included studies investigated the 
correlation between early FPG and later development of GDM. Women with overt diabetes (FPG 
values ≥7.0 mmol/L) at the first antenatal visit were excluded. Additionally, all studies used a 2-
hour, 75-g OGTT as the gold standard of diagnosis of GDM between 24 and 28 weeks gestation. 
However, not all studies defined GDM using the same threshold values (WHO, IADPSG, 
Australasian Diabetes in Pregnancy Society [ADIPS], etc.).  
FPG = 5.1 mmol/L: Two articles supported a threshold value similar to that proposed by 
the IADPSG (5.1 mmol/L). Using an FPG cutoff value of ≥ 5.1 mmol/L, Corrado et al. found an 
adjusted OR (aOR) of 7.1 (95% CI:3.8-13.1) when compared to FPG values < 5.1 mmol/L, and 
an area under the receiver operating characteristic (ROC) curve of 0.614 (95% CI: 0.544-0.684).7 
FPG < 5.1 mmol/L: Three studies examined threshold values < 5.1 mmol/L. Similar to 
IADPSG guidelines Bito et al., posit a cutoff value for FPG at ≤ 16 weeks gestation of ≥ 5.0 
mmol/L.6 This threshold value was associated with an aOR of 3.8 (95% CI: 1.1-13.4) of 
developing GDM at 24-28 gestational weeks. Additionally, this value had a negative predictive 
18 
value (NPV) of 0.92 of being diagnosed with GDM at 24-28 weeks gestation. One study 
enrolling obese women (BMI ≥ 40) concluded that an FPG of ≥ 4.7 mmol/L was an optimal 
cutoff point in this population.11 However, this study found that this value had a low sensitivity 
78.5% (95% CI:48.8%-94.2%) and specificity 43.7% (95% CI: 35.5%-52.2%). The positive 
liklihood ratio (LR) was only 1.39 (95% CI: 1.02-1.90) and the area under the ROC curve was 
unremarkable at 0.56 (95% CI: 0.39-0.72). A study by Harrison et al., enrolled high risk women 
as identified by a risk prediction tool, which included previous GDM, family history, high risk 
ethnicity, age, and BMI.13 This investigation looked at the ability of early FPG to predict GDM 
development as defined by both IADPSG and ADIPS criteria. Elevated FPG was defined in this 
study as ≥ 4.91 mmol/L (> 6.7 mmol/L was judged to be diagnostic of pre-gestational diabetes). 
This threshold value had an aOR of 6.32 (95% CI: 2.49-16.06) for predicting GDM diagnosed 
using ADIPS criteria, with a sensitivity of 34.0% and a specificity of 94.8%. In predicting GDM 
diagnosed by IADPSG criteria, this value had an aOR of 10.03 (95%CI: 3.40-29.56) with a 
sensitivity of 50.0% and a specificity of 92.4%. The area under the ROC curve was 0.79 (95% 
CI: 0.72-0.86) for ADIPS criteria and 0.83 (95% CI: 0.77-0.90) for IADPSG criteria.  
FPG > 5.1 mmol/L: Only one study investigated a higher cutoff value than that proposed 
by IADPSG.37 Median first trimester FPG was found to be 4.58 r 0.44 mmol/L across all 
women. Incidence of GDM diagnosis was strongly correlated with increase in FPG (chi-square = 
959.3, p < 0.001). The incidence of GDM development was 52.7% in women with a first 
trimester FPG between 5.6-6.09 mmol/L. The area under the ROC curve was calculated to be 
0.654 (95% CI: 0.643-0.665; SE 0.006; p < 0.001). 
Results of Systematic Reviews: A systematic review done in 2002 concluded that higher 
diagnostic threshold values should be used due to the finding that risks to the mother and fetus 
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increase linearly with increasing FPG values.29 Therefore, lower values equal lower risk, and in 
order for the benefits of screening to outweigh the costs and harms, higher threshold values must 
be used. Additionally, this study concluded that FPG values < 4.8 mmol/L may be used to 
exclude the subsequent development of GDM. This review also conceded that, although FPG 
may be an attractive screening method, data have shown that fetal weight gain may be more 
closely linked with postprandial glucose values.17 Because FPG does not test postprandial values, 
and because some women who have normal FPG levels may have elevated postprandial levels, 
Scott et al. conclude that FPG may not be the most relevant screening test for GDM and 
associated birth outcomes.  
Oral Glucose Tolerance Testing: Only one study investigated the relationship between 
early oral glucose tolerance testing and the subsequent development of gestational diabetes.31 
This study used 2-hr, 75-g OGTT at the first antenatal visit irrespective of gestational week 
(mean gestational age of these women at first antenatal visit was 23.55 weeks). A threshold value 
of ≥ 140 mg/dL was used as diagnostic of GDM according to the WHO criteria. A cohort of 
women who screened negative at their first prenatal visit, but who were subsequently diagnosed 
with GDM later in pregnancy (mean gestational age 30 weeks) were retrospectively divided into 
OGTT values < or ≥ 120 mg/dL at first antenatal screen. Of these women, 56% (who went on to 
develop GDM) had first visit OGTT levels < 120 mg/dL and 44% had values ≥ 120 mg/dL. The 
authors concluded that regardless of 2-hr OGTT results at the first antenatal visit, all women who 
test negative for GDM at this time should be rescreened at subsequent visits. 
Glycosylated Hemoglobin: The remaining two studies addressing KQ1 investigated 
Hemoglobin A1c (HbA1c) values as predictors of GDM development. The IADPSG does not 
give a threshold value for GDM diagnosis using HbA1c. They propose that physicians use a 
20 
value of ≥ 6.5% to diagnosis overt diabetes in pregnancy. These women were excluded in both 
studies. 
The first of these studies included women who received a HbA1c test at ≤ 20 gestational 
weeks.10 Those women who had a first trimester HbA1c value between 5.7-6.4% had an aOR of 
2.38 (95% CI: 1.01-5.63) for developing GDM when compared with their counterparts who had 
HbA1c values < 5.7%. The second study, found that the optimal HbA1c threshold value to 
diagnose GDM was ≥ 5.9%.16 In this study women were asked to have a 2-hr, 75-g OGTT at < 
20 weeks gestation, and the HbA1c value of ≥ 5.9% was correlated with those women who had a 
positive OGTT test. This HbA1c value was 98.4% specific (95% CI: 97.0-99.9) but only 18.8% 
(95% CI 6.6–31.1) sensitive for detection of early GDM. The area under the ROC curve for 
HbA1c and GDM correlation was 0.711. 
 
Table 3. Summary Table of Results for KQ1 
Study/Year Screening 
Test 
(Threshold) 
Gestational 
Age 
Comparator Outcomes Results 
Corrado, 
20127 
FPG (≥ 5.1 
mmol/L) 
First 
trimester 
2-hr, 75-g 
OGTT, 24-
28w 
GDM 
diagnosis 
FPG ≥ 5.1 
mmol/L: aOR = 
7.1 
Bito, 20056 FPG (≥ 5.0 
mmol/L) 
≤ 16w 2-hr, 75-g 
OGTT, 24-
28w 
GDM 
development 
FPG ≥ 5.0 
mmol/L: aOR = 
3.8 
Gandhi, 
201111 
FPG (≥ 4.7 
mmol/L) 
20w 2-hr, 75-g 
OGTT, 28w 
GDM at 28w FPG ≥ 4.7 
optimal cutoff for 
GDM prediction 
at 20w 
21 
Harrison, 
201513 
FPG (4.91-
6.70 mmol/L) 
≤ 15w 2-hr, 75-g 
OGTT, 26-
28w 
GDM 
development 
by ADIPS 
and IADPSG 
criteria 
aOR = 6.32 
predicting ADIPS 
GDM; aOR = 
10.03 predicting 
IADPSG GDM 
Zhu, 
201337 
FPG (≥ 5.6 
mmol/L) 
First 
prenatal 
visit 
(median 
13.4w) 
2-hr, 75-g 
OGTT, 24-
28w 
GDM 
development 
FPG ≥ 5.6 
mmol/L: 99% 
specificity 
Scott, 
200229 
FPG (< 4.8 
mmol/L) 
< 24w OGTT, 24-
28w 
GDM 
development 
FPG < 4.8 
mmol/L: excludes 
GDM 
Seshiah, 
200731 
OGTT (≥ 120 
mg/dL) 
First 
prenatal 
visit 
(median 
23.6w) 
2-hr, 75-g 
OGTT at 
subsequent 
visits (median 
30w) 
GDM 
development 
Of women who 
developed GDM, 
56% had early 
OGTT ≥ 120 
mg/dL, 44% had 
early OGTT < 
120 mg/dL 
Fong, 
201410 
HbA1c (≥ 
5.7%) 
≤ 20w One or two 
step OGTT at 
24-28w 
GDM 
development 
HbA1c ≥ 5.7%: 
aOR = 2.38 
Hughes, 
201416 
HbA1c (≥ 
5.9%) 
< 20w One or two 
step OGTT at 
24-28w 
GDM 
development 
HbA1c ≥ 5.9%: 
100% sens, 
97.4% spec; 
HbA1c < 4.8%: 
excludes GDM 
 
 
FPG: Fasting plasma glucose  
HbA1c: hemoglobin A1c (glycosylated hemoglobin) 
OGTT: Oral glucose tolerance test 
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KQ2: Early screening and pregnancy outcomes 
The second interest of this review is to determine if early screening for gestational 
diabetes mellitus leads to better birth outcomes for the mother and the neonate. Only two studies 
showed any benefit for early screening. And this was seen only in selected outcomes. The 
majority of maternal and fetal outcomes were not different in women who were screened early 
than in those who were screened later. Two studies actually reported worse maternal and fetal 
outcomes in women who were identified through early screening than those identified in the 
second trimester (see Table 4 for a summary of articles addressing KQ2).  
Macrosomia and Large for Gestational Age: Of the seven studies addressing KQ2, four 
found similar birthweights and rates of LGA and macrosomic infants born to mothers screened 
for GDM early versus those screened in the second trimester. Hivert et al. found similar 
birthweights (kg) (early = 3.360 [3.080-3.690], traditional = 3.380 [3.040-3.650]) and rates of 
macrosomia between those who received early screening and traditional screening.15 Hawkins et 
al. found similar rates of LGA and macrocosmic infants in both early and traditional cohorts after 
adjusting for maternal age, race, parity, weight, and glycemic control.14 Another study found no 
differences in neonatal outcomes between women screened before 20 weeks gestation and 
women screened at or after 20 weeks gestation.10 A similar study from 2015 found similar 
birthweights and rates of macrosomia in infants born to mothers screened before or after 24 
weeks gestation.4  
A study from 2009 found that rates of  LGA (18% vs. 6% [P=0.02]) and macrosomia 
(14% vs. 6% [P=0.001]) were twice as high (1.8% vs 4.4%) among infants born to mothers 
identified through first trimester screening.24 Although the data seem to suggest that early 
screening does not decrease the rates of LGA and macrocosmic infants, the 2002 systematic 
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review by Scott et al. concluded that the utility of early screening should not be decided based on 
rates of macrosomia.29 These authors argue that macrosomia is an intermediate outcomes and not 
a relevant clinical outcome. The utility of early screening must be evaluated by looking at 
reduction of harmful health outcomes.  
Cesarean Delivery: Four studies investigated rates of cesarean delivery associated with 
timing of screening. Two of these studies4,10 found that rates of C-section did not change 
between mothers screened earlier, and those screened in the second trimester. Most et al. found 
rates of cesarean delivery to be 45% in the early diagnosis group and 24% in the late diagnosis 
group (P=0.002),24 and Hawkins et al. found a non-statistically significant increase in the odds 
ratio of repeat cesarean delivery among this group.14 Taken together the data suggest that earlier 
screening may not reduce rates of cesarean delivery and may actually increase rates when 
compared to traditional diagnostic measures. 
 Gestational Age and Preterm Birth: The data found a similar story regarding rates of 
preterm birth and gestational age at delivery. Alunni et al. and Hivert et al. found an average 
gestational age at delivery of 39 weeks in both early screening and late screening cohorts.4, 15 
Two studies found increased risk of preterm birth in the early screening population. Most et al. 
did not find a statistically significant difference between groups, however 6.1% of the early 
cohort in comparison with 5.4% of the late cohort were born preterm (P=0.79).24 Hawkins et al. 
attributed this to higher rates of preeclampsia (aOR=2.4 [95% CI:1.5-3.8]) leading to early 
delivery.14 
Preeclampsia: Only three studies investigated preeclampsia as a maternal outcome as it 
relates to GDM screening. Two found maternal outcomes such as preeclampsia were worse for 
women identified through early screening.14, 24 Most et al. found a non-significant increase in 
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hypertension among mothers identified earlier (19.4%) compared to mother identified later 
(12.4%; P=0.10). The last study found no difference in rates of maternal preeclampsia between 
early and traditional cohorts.4 
Shoulder Dystocia: Only two studies addressed shoulder dystocia as an outcome of 
interest and these studies found opposing results. One study by Hawkins et al. concluded that 
women with diet-treated GDM who were identified before 24 weeks had lower rates of cesarean 
deliveries for dystocia (3%) than women with diet-controlled diabetes mellitus identified at or 
later than 24 weeks gestation (6%; p = 0.02).14 In direct contrast to that data, the study by Most et 
al. found increased rates of shoulder dystocia in the early screening cohort leading to a mixed 
picture surrounding shoulder dystocia.24 
NICU Admission and Stillbirth: Of three studies which looked at rates of NICU 
admissions and/or stillbirth, one found that early screening in the setting of a specialized diabetes 
clinic led to decreased rates of neonatal intensive care unit (NICU) admissions (15.4%) 
compared to second trimester screening (20.8%; P=0.002).15 Two papers found similar rates of 
neonatal complications between the two cohorts (including NICU admission and intrauterine 
fetal demise [IUFD or stillbirth]). A systematic review done of the literature published prior to 
2010 concluded that it was not possible to show that early testing was superior to later testing in 
improving rates of stillbirth.34 This review found only one study and one review article 
investigating the relationship between early GDM screening and IUFD. This review also 
concluded that threshold values or guidelines used to screen for and diagnose GDM (ADA vs. 
WHO) had no bearing on stillbirth rates. This conclusion was based on data from two 
observational studies. 
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Outcomes and First Trimester HbA1c: One study was identified that compared first 
trimester hemoglobin A1c value (HbA1c) with perinatal outcomes.16 This study proposed an 
early HbA1c threshold value of 5.9%. In women with elevated first trimester HbA1c, risk of 
preterm birth was elevated with an aOR of 1.66 (95% CI: 1.01-2.74), as well as risk of shoulder 
dystocia (aOR=2.48 [95% CI:1.21-5.10]) and preeclampsia (aOR=3.04 [95% CI: 1.97-4.70]). 
Risk of perinatal death was also found to be higher in this population though the odds ratio was 
not significant after adjusting for confounders (aOR=2.24 [95% CI: 0.75-6.69]). 
 
Table 4. Summary Table of Results for KQ2 
Study/Year Screening 
Test 
(Threshold) 
Gestational 
Age 
Comparator Outcomes Results* 
Hawkins, 
200814 
RPG (≥ 130 
mg/dL) 
< 24w Two step 
OGTT at 24-
28 weeks 
Preeclampsia, 
repeat cesarean, 
SHD, LGA, 
macrosomia 
Decreased 
cesarean for 
dystocia in early 
group; no 
difference in LGA 
or macrosomia; 
increased 
preeclampsia and 
cesarean 
Hivert, 
201215 
1-hr GCT (≥ 
10.3 mmol/L) 
First 
trimester (0-
13w) 
GCT in the 
second 
trimester 
Duration of 
gestation, 
cesarean, 
neonatal comp, 
NICU, bwt, 
macro 
Decreased NICU 
in early group; no 
difference in 
duration of 
gestation, 
cesarean, neonatal 
comp bwt, macro; 
increased 
Fong, 
201410 
HbA1c (≥ 
5.7%) 
≤ 20w One or two 
step OGTT 
at 24-28w 
Cesarean, 
NICU, bwt, 
macro, IUFD 
All outcomes 
equal in both 
groups 
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Alunni, 
20154 
HbA1c (≥ 
5.7%) or FPG 
(≥ 92 mg/dL) 
≤ 24w 2-hr, 75-g 
OGTT at 24-
28 weeks 
Maternal and 
neonatal 
outcomes, 
delivery mode, 
gestational age 
at delivery 
All outcomes 
equal in both 
groups 
Syed, 
201134 
Not specified First 
trimester 
Regular 
screening 
(24-28w) 
Stillbirth No difference in 
stillbirth 
Most, 
200924 
50-g GCT (≥ 
140 mg/dL) 
and 100-g 
OGTT 
First 
trimester 
OGTT at 24-
28 weeks 
Macro, LGA, 
cesarean, 
preterm, SHD, 
preeclampsia 
Increased rates of 
all outcomes in 
early group 
Hughes, 
201416 
HbA1c (≥ 
5.9%) 
< 20w One or two 
step OGTT 
at 24-28w 
Preeclampsia, 
SHD, stillbirth, 
preterm 
HbA1c ≥ 5.9%: 
increased rates of 
all outcomes 
 
*Results: Results report increase, decrease, or no change in magnitude of effect (not necessarily 
statistically significant) 
GCT: Glucose Challenge Test 
Bwt: birthweight 
Macro: Macrosomia 
Neonatal comp: neonatal complications 
NICU: neonatal ICU admission 
Preterm: Preterm birth 
SHD: Shoulder dystocia 
 
Discussion: 
Interpretation of the Evidence: The risk of bias of each individual study was assessed, 
and internal and external validity was assessed (see Table 4 for risk of bias within each study). 
The data supporting the accuracy of early screening for gestational diabetes are mixed. The 
majority of the data to date have investigated fasting plasma glucose prior to 20 weeks gestation 
as the optimal test for early GDM screening. Fewer studies have used oral glucose tolerance 
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testing or glycosylated hemoglobin, but both of these methods are also of interest for use during 
early pregnancy.   
Current international guidelines recommend using a fasting plasma glucose value of ≥ 5.1 
mmol/L as a threshold value for diagnosing GDM. Studies have shown that FPG values change 
throughout pregnancy, and this review found evidence supporting threshold values from 4.7 
mmol/L to 6.1 mmol/L as optimal cutoff values for early GDM screening. One systematic review 
proposed that a value of < 4.8 mmol/L could be used to rule out the future development of 
gestational diabetes mellitus at early screening.  
Oral glucose tolerance testing has also been investigated and suggested cutoff values 
range from ≥ 140 mg/dL to ≥ 153 mg/dL for early diagnosis of GDM. Additionally, values < 140 
mg/dL have not been found to be sensitive for ruling out GDM development later in pregnancy, 
and women who screen negative at their first antenatal visit should be screened again during the 
second trimester regardless of the results of their first OGTT. Fewer guidelines exist regarding 
the use of HbA1c as a diagnostic test in pregnancy. This is partially attributable to the fact that 
most data on optimal HbA1c thresholds come from studies done in non-pregnant populations. 
The studies investigating HbA1c values suggest using a cutoff between 5.7-5.9% as predictive of 
GDM development in pregnancy.  
Although various threshold and cutoff values for early screening and diagnosis of GDM 
have been posited by different national and international organizations, the available literature 
has yet to support a common value in all situations. This is likely due, in part, to the fact that 
rates of and risk factors for gestational diabetes vary by ethnicity, by region, by setting, by 
lifestyle, and by genetics. Therefore, it is possible that the present search for an international 
consensus on guidelines is not feasible. The literature has also demonstrated consistently that 
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there is a linear relationship between blood glucose in pregnancy and the associated negative 
outcomes. This suggests that any amount of elevation in blood glucose levels during pregnancy 
increases a woman’s risk of developing harmful outcomes and should therefore be considered 
abnormal. However, it also suggests that any level chosen as a threshold will necessarily be 
somewhat arbitrary.   
In accordance with KQ2, additionally, none of these methods of early screening for, or 
detection of, GDM have been consistently linked to better pregnancy outcomes. The large 
majority of studies included found no differences in pregnancy or birth outcomes for those 
women who received early screening when compared to those women who received standard, 
second trimester screening. Infrequently, single outcomes in various studies were found to 
improve among the group who received earlier screening, but these findings were not 
reproducable in other studies.  
Furthermore, women who were diagnosed with GDM earlier in pregnancy were often 
found to have higher rates of pregnancy complications than those diagnosed later. This is likely 
due to the study design of these studies. Instead of using two cohorts of women, one who 
received earlier screening, and one who received later screening, all of these studies used the 
same cohort of women. These women received early screening, and then those who tested 
negative early in pregnancy were screened again in the second trimester. Therefore, rather than 
measuring the effects of early screening on outcomes, these studies were actually measuring 
early onset versus later onset development of GDM. This means that those who were diagnosed 
earlier in pregnancy likely had more severe cases of GDM and fetuses were exposed to elevated 
blood glucose levels for a longer period of time, likely leading to the conclusion that earlier 
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screening and diagnosis leads to worse outcomes. In the future studies should screen different 
cohorts of women in the first and second trimesters to avoid this confounding effect.  
A potential source of confounding across studies was that not all studies defined ‘early 
screening’ the same. All included studies performed screening prior to the traditional 24 weeks 
gestation, but in some cases it was limited to screening before 15 or 16 weeks, and the median 
values for gestational age of women who received early screening varied widely between the 
studies. This could cause results to vary based on when early screening was performed and GDM 
was identified. The tests used to perform early screening in the studies on KQ2 varied widely 
between studies. This might cause variability in results between studies. However, despite this 
potential source of confounding, these studies overwhelmingly found similar results (i.e. no 
difference between early and late screening). This increases our confidence in the conclusions of 
this review. Furthermore, many different sets of criteria were used across the body of literature. 
While this should not have affected numerical values and cutoff points, it may have affected 
outcomes associated with ‘early identification’ if that definition changed across studies.  
Some experts have expressed concern that fasting plasma glucose may be suboptimal to 
investigate fetal and maternal outcomes in relation to gestational diabetes. This is because 
postprandial glucose levels have been implicated in macrosomia and adverse pregnancy 
outcomes. FPG does not take postprandial glucose levels into account and may result in false 
negatives, when the fetus is actually being exposed to higher than normal levels of glucose in 
utero. Therefore, hemoglobin A1c was judged by the author to be the ideal method for first 
trimester screening. This is to limit the number of women who have to undergo oral glucose 
tolerance testing and to capture a more comprehensive picture of glucose levels (both fasting and 
postprandial) which may lead to negative pregnancy outcomes. 
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Table 5. Risk of Bias by Individual Study 
Study Potential for 
selection bias 
(+ to +++) and 
explain  
Potential for 
measurement 
bias (+ to 
+++)  
Potential for 
confounding 
(+ to +++)  
Overall 
judgment 
of internal 
validity 
(good, 
fair, poor)  
External 
validity: 
applicability to 
other 
populations  
Alunni, 
20154 
++ Initial 
comparability: 
Early screen 
group - fewer 
RFs; Dropouts: 
None 
++/+++ Equal: 
Cohorts from 
different times; 
Valid: 
Phamacotx as 
surrogate 
marker; 
Reliable: Good 
++ Adjusted 
for BMI as 
only 
confounder 
Fair Maternal and 
neonatal 
implications 
unknown. 
Applicable to US 
populations but 
unsure about 
international 
Bito, 
20056 
++/+++ Initial 
comparability: 
NR; Dropouts: 
None 
++ Equal: NR; 
Valid: WHO 
criteria; 
Reliable: Good 
++/+++ NR Fair/Poor 
Lack of 
transparenc
y. 
Unsure about 
applicability 
across races. No 
assessment of 
lifestyle 
differences 
Corrado, 
20127 
++/+++ Initial 
comparability: 
Fair; Dropouts: 
Small number 
(due to 
inadequate 
data) 
++ Equal: 
Many labs ran 
tests; Valid: 
IADPSG 
criteria; 
Reliable: Good 
+/++ Adjusted 
for maternal 
age and pre-
pregnancy 
BMI 
Fair Caucasian 
population - 
difficult to 
extrapolate to 
other races and 
other healthcare 
settings 
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Fong, 
201410 
++ Initial 
comparability: 
Interest group 
with more risk 
factors; 
Dropouts: 
None 
++ Equal: Two 
screening 
methods; 
Valid: Early 
A1c not 
validated; 
Reliable: Good 
+ Adjusted for 
age, 
race/ethnicity, 
pre-pregnancy 
BMI, 
gestational age 
at HbA1C 
sample 
collection, 
gestational age 
at GDM 
screening/diag
nosis, and 
method of 
GDM 
screening (2-
step vs. 1-step) 
Good  Primarily 
Hispanic 
population with a 
high prevalence 
of obesity - may 
not apply to 
different 
demographics 
Gandhi, 
201111 
++/+++ Initial 
comparability: 
Good; 
Dropouts: 
large number 
excluded due 
to failure to 
have tests at 20 
and 28 weeks. 
+ Equal: Good; 
Valid: Good; 
Reliable: Good 
+++ Not 
adjusted for 
significant 
confounders 
Fair Obese, Caucasian 
population. 
Limited 
information on 
GDM risk factors. 
Harrison, 
201513 
++ Initial 
comparability: 
Good; 
Dropouts: 
Some lost to 
follow-up 
+ Equal: Good; 
Valid: Good; 
Reliable: Good 
+ Adjusted for 
age, baseline 
BMI, 
ethnicity, 
previous GDM 
and family 
history of 
T2DM 
Good/Fair  High risk 
population may 
not be 
generalizable. 
Tool not validated 
in BMI < 25. 
Ethnically diverse 
study population 
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Hawkins, 
200814 
++/+++ Initial 
comparability: 
Early 
screening only 
in high-risk; 
Dropouts: 
More early 
screen likely to 
be ineligible 
++ Equal: 
Good; Valid: 
National 
Diabetes Data 
Group criteria; 
Reliable: Good 
+/++ Adjusted 
for 
demographics 
and 
lifestyle/glyce
mic control 
Fair Largely Hispanic 
population. 
Screening 
guidelines 
different in 
different countries 
Hivert, 
201215 
+/++ Initial 
comparability: 
Groups from 
different 
settings; 
Dropouts: 
None 
++ Equal: 
Cohorts from 
different 
times/settings; 
Valid: Good; 
Reliable: Good 
+++ Unable to 
adjust for pre-
pregnancy 
BMI and 
family history 
Fair Specialty clinic 
may be increase 
interaction with 
health care 
providers or more 
intense 
monitoring 
Hughes, 
201416 
++/+++ Initial 
comparability: 
higher risk 
factors in 
higher BMI 
group; 
Dropouts: 
High 
+ Equal: Good; 
Valid: Good; 
Reliable: Good 
+++ Outcome 
frequencies 
too low to 
adjust for 
potential 
confounders 
Fair Primarily low-risk 
Caucasian 
population  
Most, 
200924 
++ Initial 
comparability: 
Fair; Dropouts: 
NR 
+/++ Equal: 
Good; Valid: 
Dependent on 
criteria; 
Reliable: Good 
+/++ Adjusted 
for maternal 
age. ethnicity, 
BMI, parity, 
previous 
cesarean 
delivery 
Good/Fair Inner city, largely 
Hispanic and 
Asian populations 
Scott, 
200229 
+ Multiple 
reviewers 
++ Equal: 
Non-
transparent 
measurement; 
Valid: Good; 
Reliable: Good 
++ NR Good/Fair International 
guidelines. Good 
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Seshiah, 
200731 
++ Initial 
comparability: 
Few 
demographic 
collected; 
Dropouts: NR 
++/+++ Equal: 
Cohorts from 
different times 
Valid: WHO 
criteria 
Reliable: Good 
+++ Not 
adjusted for 
age/BMI 
Poor Done in India, 
few demographics 
reported. Difficult 
to extrapolate. 
Syed, 
201134 
+ Multiple 
reviewers 
+ Equal: Re-
ran all 
calculations; 
Valid: Meta- 
Analysis; 
Reliable: Good 
++ NR Good Developing and 
developed 
countries. Good 
Zhu, 
201337 
++ Initial 
comparability: 
Fair; Dropouts: 
None 
++ Equal: 
Good; Valid: 
Chinese MOH 
criteria 
Reliable: Good 
++ Adjusted 
for age and 
different 
testing 
locations. Did 
not adjust for 
BMI 
Good/Fair Chinese 
population and 
guidelines used. 
 
NR: Not reported 
 
Limitations: There were several limitations associated with the available body of 
evidence. The most significant limitation identified was a lack of randomized controlled trials. 
This is possibly due to a prevailing hesitancy to randomize pregnant women to interventions that 
may be harmful or have not been shown to improve outcomes for women and their babies. 
Additionally, many of the established guidelines and criteria are based off of data collected in 
non-pregnant populations and may not be applicable or appropriate criteria to apply to screening 
pregnant women.  
The limitations of this review are twofold. The review was performed by a single 
reviewer, increasing the risk of bias of study selection and quality ratings. Additionally, only two 
databases were searched, and only articles published in English were able to be included due to 
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constraints on time and personnel. It is likely that articles exist in other journals and languages 
that investigated out questions of interest but were not included.  
Future Directions: Due to the lack of evidence supporting better outcomes in those 
women who receive earlier screening and interventions, randomized controlled trials to 
investigate the accuracy and utility of first trimester GDM screening would be ethically 
justifiable. RCTs are needed both that establish accuracy of the available tests and the best 
thresholds, as well as studies that investigate maternal and neonatal outcomes of early screening 
versus standard screening. 
Secondly, the gold standard oral glucose tolerance test is an unpleasant tool that is not 
well tolerated by many pregnant women. Therefore, in addition to searching for highly specific 
first trimester tests which predict or diagnose GDM, there would be high clinical utility in the 
discovery of a highly sensitive test or threshold value that could rule out GDM development. 
This test would allow women with very low risk to forgo the second trimester OGTT and its 
associated burdens, as well as decreasing rates of false positives.  
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Appendix A. PubMed Search Strategy: the following search strategy was used for the PubMed 
database:  
("diabetes, gestational"[MeSH Terms] OR ("diabetes"[All Fields] AND "gestational"[All 
Fields]) OR "gestational diabetes"[All Fields] OR ("gestational"[All Fields] AND 
"diabetes"[All Fields])) AND ("pregnancy outcome"[MeSH Terms] OR ("pregnancy"[All 
Fields] AND "outcome"[All Fields]) OR "pregnancy outcome"[All Fields]) AND ("mass 
screening"[MeSH Terms] OR ("mass"[All Fields] AND "screening"[All Fields]) OR 
"mass screening"[All Fields]). Searches results were filtered to include only studies done 
since 2002 and studies done in humans. 
 
Appendix B. USPSTF Quality Rating Criteria. Adapted from PubMed Health. Accessed at 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0009125/ on 6 June 2016. 
Initial comparability of 
groups 
 RCTs—adequate randomization, including concealment and 
whether potential confounders were distributed equally among 
groups; cohort studies—consideration of potential confounders with 
either restriction or measurement for adjustment in the analysis; 
consideration of inception cohorts 
Maintenance of 
comparable groups 
Includes attrition, cross-overs, adherence, contamination 
Loss to follow-up Important differential loss to follow-up or overall high loss to 
follow-up 
Measurements Equal, reliable, and valid (includes masking of outcome 
assessment) 
Interventions Clear definition of interventions 
Outcomes Important outcomes considered 
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Analysis Adjustment for potential confounders for cohort studies, or 
intention-to-treat analysis for RCTs (i.e. analysis in which all 
participants in a trial are analyzed according to the intervention to 
which they were allocated, regardless of whether or not they 
completed the intervention) 
 
 
 
Appendix C. Data Extraction Tables - by Study 
Study 1 
KQ1 
Alunni, M. L., Roeder, H. A., Moore, T. R., et al. (2015) First trimester 
gestational diabetes screening- change in incidence and 
pharmacotherapy need 
Study Question: How do GDM diagnosis rates compare using the standard two-step 
approach versus early screening and secondarily how do 
pharmacotherapy needs and perinatal outcomes compare? 
Source of Funding: NR 
Source Population: Two cohorts from the California Diabetes and Pregnancy Program at 
UCSD. Total UCSD prenatal population 
Study Population: Singleton pregnancies diagnosed between 7/2010 and 6/2012. Two 
cohorts identified by review of clinic dataset and electronic chart 
review. Excluded: pts with multiple gestations, pre-pregnancy T1DM or 
incidental dx of T2DM (A1C ≥ 6.5% or FPG ≥ 126 in first trimester.  
Design: Retrospective cohort study 
Intervention: Women diagnosed early (HbA1C  ≥ 5.7% or FPG ≥ 92mg/dL at ≤ 24 
weeks)  
Intervention Setting: UCSD Diabetes and Pregnancy Program (DAPP)  
Comparison: Women diagnosed at 24-28 weeks (2-hr OGTT) 
42 
Measurement: No info on total number screened - so no data on rates of dx. Maternal 
age, parity, BMI, and ethnicity were abstracted from EMR. Maternal 
outcomes: mode of delivery and gestational age at delivery. Neonatal 
birth weight and length (for ponderal index). Early diagnosis cohort 
analyzed to calculate proportions of pts dx with GDM via A1C, FPG, 
and OGTT to determine pharmacotherapy as well as gestational age at 
initiation of pharmacotx. No info on those who screened negative 
therefore no predictive values of screening.  
Results: BMI strongest predictor of need for pharmacotherapy. But method of 
dx remained significant. At an HbA1C of 5.7%-5.9% over half of pts 
required pharmacotx. Over 70% of those diagnosed with FPG 
elevations needed meds. Maternal and neonatal outcomes of mode of 
delivery and gestational age at delivery were similar for all groups. 
Neonatal outcomes of weight and ponderal index did not differ 
Attrition: No dropouts, retrospective data collection. No data on those who 
screened negative 
Quality Score: Fair 
 
 
 
 
Study 2 
KQ1 
Bito, T., Nyari, T., Kovacs, L., & Pal, A. (2005). Oral glucose 
tolerance testing at gestational weeks d 16 could predict or exclude 
subsequent gestational diabetes mellitus during the current pregnancy 
in high risk group 
Study Question: What OGTT cut-off values at gestational age ≤ 16 weeks can predict or 
exclude subsequent onset of GDM in a high risk group? 
Source of Funding: Not reported 
Source Population: 163 pregnant women at high risk of gestational diabetes. 
43 
Study Population: 155 women who had not had prior GDM or altered carbohydrate 
metabolism in a previous pregnancy, but who had one or more risk 
factors and were enrolled at ≤ 16 weeks gestation. Family history of 
T2DM, history of large neonate, history of adverse perinatal outcome, 
obesity, and age were all risk factors. Included women were not 
opposed to any medication or dietary restriction. Eight patients were 
excluded from the further analysis as GDM was diagnosed by this first 
OGTT at gw ≤ 16. 
Design: Prospective observational study 
Intervention: 2-hr 75-g OGTT at ≤ 16 weeks and FPG 
Intervention Setting: Women referred to a special Diabetic Pregnant Outpatient Department 
in Hungary 
Comparison: 2-hr 75-g OGTT at 24-28 weeks; 2-hr 75-g OGTT at 32-34 weeks 
Measurement: 2-hr 75-g OGTT and FPG. Patients were considered to have GDM in 
the event of a glucose level of ≥ 7.0mmol/L fasting or ≥ 7.8 mmol/L at 
120 min according the WHO criteria. Incidence of family history of 
T2DM, history of large neonate, adverse perinatal outcome, obesity and 
age and glycosuria were all recorded (unclear if used medical records or 
patient self-report) 
Results: 54% of high-risk women developed GDM. 4.9% at ≤ 16 gw; 19.6% at 
24-28 gw; 29.4 % at 32-34 gw. Best cut-off value for fasting glucose 
was ≥ 5 mmol/l: OR=3.8 (1.1-13.4) for developing GDM at 24-28 
weeks. No correlated risk at 32-34 weeks. Best post load level 6.2: OR 
= 7.5 (1.0-57.8) at 24-28 wks and OR = 2.6 (1.1-6.5) at 32-34 wks. 
Combined 5.3 and 6.8 with obesity is strongest predictive factor for 
GDM at 32-34 weeks. OR = 6.0 (1.7-21.0) 
Attrition: No loss to follow-up 
Quality Score: Poor/Fair 
 
 
 
 
Study 3 
KQ1 
Corrado, F., D’Anna, R., Cannata, M. L., et al. (2012). Correspondence 
between first-trimester fasting glycaemia and oral glucose tolerance 
test in gestational diabetes diagnosis. 
44 
Study Question: What is the correspondence between first-trimester fasting glycaemia 
and the results of the OGTT in diagnosing gestational diabetes? 
Source of Funding: Not reported 
Source Population: 775 consecutive Caucasian pregnant women scheduled for OGTT early 
in 3rd trimester 
Study Population: 738 eligible patients. Exclusions due to twin pregnancy, no first 
trimester FPG assay, or FPG diagnostic of pre-gestational diabetes 
Design: Retrospective cohort study 
Intervention: First trimester fasting plasma glucose 
Intervention Setting: Department of Obstetrics and Gynecology, University of Messina, Italy 
Comparison: 2-hr 75-g OGTT at 24-28 weeks according to the IADPSG guidelines 
Measurement: 2-hr 75-g OGTT according to the IADPSG Consensus Panel Criteria. 
Women were asked to provide first trimester FPG results (not all done 
at same lab). If this value was < 7.0 mmol/l they underwent OGTT and 
were evaluated according to IADPSG criterial. Lab was blinded to and 
pre-existing values of FPG. At end of trial period women’s charts were 
reviewed and correspondence between the two different diagnostic 
strategies compared. 
Results: 11.9% of eligible patients diagnosed with GDM according to ADA. 
When ≥ 5.1 mmol/L was used as a cutoff for first trimester screening 
crude OR = 8.0 (4.4-14.6) and adjusted OR = 7.1 (3.8-13.1) 
Attrition: 18 did not have first trimester FPG and 6 had FPG value after first 
trimester. One excluded b/c first trimester FPG diagnostic of diabetes 
Quality Score: Fair 
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Study 4 
KQ1 
Fong, A., Serra, A. E., Gabby, L., et al. (2014). Use of hemoglobin A1c 
as an early predictor of gestational diabetes mellitus 
Study Question: Can an early HbA1C value of 5.7-6.4% be used as an early predictor of 
progression to GDM? 
Source of Funding: NR 
Source Population: All women who delivered at a single institution over 2 years who had 
an early screening HbA1C test performed at ≤ 20 weeks of gestation. 
Study Population: 526 women met inclusion criteria. Women were included if they had a 
screening HbA1C test at ≤ 20 0/7 weeks of gestation and had been 
delivered by our practice from Jan 2011 to Jan 2013. Women with 
known preexisting diabetes mellitus or HbA1C values ≥ 6.5% were 
excluded. Or if they did not undergo screening or did not deliver at the 
institution 
Design: Retrospective cohort study 
Intervention: HbA1c at ≤ 20 weeks gestation 
Intervention Setting: MemorialCare Center for Women at Miller Children’s Hospital in Long 
Beach, CA  
Comparison: 1 step (2-hr, 75-g) or 2 step (1-hr, 50-g & 3-hr, 100-g) OGTT at 24-28 
weeks gestation 
Measurement: Two different screening methods included, may increase ROB. Primary 
outcomes: GDM development. Secondary outcomes: delivery route, 
maternal weight gain, birthweight, and neonatal morbidities (NICU 
admission, neonatal hypoglycemia, hyperbilirubinemia, transient 
tachypnea, or acute respiratory distress) (5-minute Apgar score < 7, 
birthweight, macrosomia, SGA, fetal demise). Blinding not discussed.  
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Results: Women with HbA1c levels 5.7-6.4% had 2.4 fold higher odds of the 
development of GDM when compared with HbA1c < 5.7% 
counterparts. No statistically significant difference b/w groups on who 
needed medical treatment. No difference in C-section or weight gain. 
Mean 1-hr OGTT significantly higher in 5.7-6.4 group as was fasting 
glucose. Neonatal outcomes - no difference in composite adverse 
neonatal outcomes (NICU admission, hypoglycemia, 
hyperbilirubinemia, transient tachypnea, or acute respiratory distress), 
low Apgar, birthweight, macrosomia, SGA, IUFD. Subgroup analyses: 
A1c ≤ 14 0/7 weeks to evaluate 1st trimester. Significantly more in the 
5.7-6.4 group developed GDM. Second subgroup, obese women 
(prepregnancy). In obese pts - those in the 5.7-6.4 group more 
significantly more likely to develop GDM. In non-obese, no significant 
difference.  
Attrition: None 
Quality Score: Good 
 
 
 
 
Study 5 
KQ1 
Gandhi, P., & Farrell, T. (2011) Gestational diabetes mellitus (GDM) 
screening in morbidly obese pregnant women. 
Study Question: What are the outcomes of two-stage GDM screening of morbidly obese 
women, and what is the diagnostic performance of 20-week OGTT 
values in predicting or excluding late onset GDM? 
Source of Funding: No external sources of funding 
Source Population: 295 pregnant women with BMI ≥ 40 who delivered in the center 
Study Population: 190 women with BMI ≥ 40. Women who followed the GDM screening 
protocol. Exclusion: women with pre-existing diabetes mellitus, 
previous gestational diabetes and who failed to attend OGTT at either 
20 or 28 weeks were excluded 
Design: Retrospective cohort study 
Intervention: 2-hr, 75-g OGTT at 20 weeks and fasting plasma glucose 
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Intervention Setting: High BMI clinic at the Royal Hallamshire Hospital, Sheffield, UK 
Comparison: 75-g OGTT at 28 weeks gestation 
Measurement: All samples measured at the same site and the machine calibrated 
yearly for quality assurance. All women measured at same gestational 
age 
Results: Glucose ≥ 6mmol/L was the optimal cutoff value for the 2-h OGTT to 
predict GDM at 28 weeks. Fasting glucose ≥ 4.7 was optimal cutoff for 
fasting glucose levels at 20 weeks OGTT. Positive likelihood ratio 2.19 
and negative likelihood ratio of 0.12.  
Attrition: 105 women excluded: 39 had normal OGTT at 20 weeks but did not 
follow-up at 28 weeks. 20 had first OGTT test at 28 weeks. 38 did not 
have the test either at 20 or 28 weeks.  
Quality Score: Fair 
 
 
 
 
Study 6 
KQ1 
Harrison, C. L., Lombard, C. B., East, C., et al. (2015). Risk 
stratification in early pregnancy for women at increased risk of 
gestational diabetes. 
Study Question: Can fasting glucose and lipids be added to a simple, validated risk 
prediction tool for GDM applied in early pregnancy? 
Source of Funding: BRIDGES grant from the International Diabetes Federation (supported 
by an education grant from Lilly Diabetes). And the Jack Brockhoff 
Foundation 
Source Population: Women at risk of developing GDM on a validated risk prediction tool 
(developed using retrospective cohort in 2008) 
Study Population: Recruitment at three large tertiary teaching hospitals in metropolitan 
Melbourne (2008-2010). Invited to participate by invitation letter if ≤ 
15 weeks gestation, had singleton pregnancy, were overweight or obese, 
and at increased risk of GDM on risk prediction tool. Exclusion criteria: 
diagnosed T1DM or T2DM, non-English speaking, pre-existing chronic 
medical condition.  
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Design: Prospective cohort study - as part of a larger randomized controlled trial 
Intervention: Early pregnancy fasting plasma glucose 
Intervention Setting: Three large tertiary teaching hospitals in metropolitan Melbourne, 
Australia 
Comparison: 2-hr, 75-g OGTT at 26-28 weeks gestation 
Measurement: This is one part of a larger study which investigated the addition of 
biochemical measures to a previously validated risk prediction tool. 
Focus on impact of fasting blood glucose and lipid measurement taken 
in early pregnancy on GDM risk prediction. All outcomes measures 
were completed at baseline (12-15 weeks) and 26-28 weeks. Basic 
demographic data collected at baseline. Venous blood sampling for 
biochemical markers. At 26-28 weeks women did 1 step OGTT to 
assess for GDM. All data pooled and stratified according to GDM 
outcome. 
Results: Baseline characteristics did not vary between GDM and non-GDM 
groups. Fasting glucose and triglycerides were higher in the GDM 
groups diagnosed using both ADIPS and IADPSG. For IADPSG GDM 
women they had higher proportion of previous GDM and higher age. 
Those with higher baseline plasma glucose had significantly higher 
weight, fat mass, and lower HDL in early pregnancy and higher OGTT 
later in pregnancy than those with lower plasma glucose in early 
pregnancy. Elevated fasting triglyceride and glues predicted ADIPS 
GDM (adjusted and unadjusted). Elevated fasting triglycerides, glucose, 
and low HDL predicted IADPSG GDM. Fasting glucose strongest 
predictor for both groups 
Attrition: 10% misdirected to have (Australian) standard 50-g glucose challenge 
test and did not progress to OGTT 
Quality Score: Fair/Good 
 
 
 
Study 7 
KQ1 
Hawkins, J. S., Lo, J. Y., Casey B. M., et al. (2008). Diet-treated 
gestational diabetes mellitus: Comparison of early vs routine diagnosis 
Study Question: How do pregnancy outcomes compare in women with diet treated GDM 
diagnosed at < 24 weeks to those diagnosed at ≥ 24 weeks.  
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Source of Funding: NR 
Source Population: 87,057 women delivered between 1999 and 2005 
Study Population: 2257 women with diet treated GDM screening for GDM between 24-28 
weeks unless they had glucosuria, random serum glucose ≥ 130 mg/dL, 
history of GDM, or symptoms such as polydipsia or polyuria (these 
women were screened immediately). Women who were identified to 
have diet treated GDM, singleton pregnancy, and cephalic fetuses 
without major fetal malformations. Excluded: non-cephalic infants, and 
insulin treated diabetes 
Design: Retrospective cohort study 
Intervention: Women with diet-treated GDM that was diagnosed at < 24 weeks 
Intervention Setting: Parkland Hospital  
Comparison: Women with diet-treated GDM that was diagnosed at ≥ 24 weeks 
Measurement: All women received screening between 24-28 weeks unless showed risk 
factors. Then were given two step OGTT and diagnosed based on 
National Diabetes Data Group thresholds. If negative, women were 
tested again at 24-28 weeks. Pregnancy outcomes entered into a 
computer operations database. Antepartum info entered into separate 
database and linked electronically to pregnancy outcome data. LGA and 
shoulder dystocia 
Results: Women with early dx more likely to be older, multip, and obese. 
Women with early diagnosis had significantly higher mean results for 
the 50-g OGTT. Early dx had higher mean fasting glucose but also 
greater decrease in fasting glucose throughout pregnancy. Women with 
early dx had higher rates of preeclampsia leading to early gestational 
age at delivery, higher rate of repeat cesarean deliveries but fewer for 
dystocia. Infants more likely to be LGA and hyperbili. LGA did not 
persist when adjusted for demographic characteristics and weight 
Attrition: 398 of those diagnosed before 24 weeks were treated with insulin and 
therefore ineligible. 679 of those diagnosed after 24 weeks treated w/ 
insulin 
Quality Score: Fair 
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Study 8 
KQ1 
Hivert, M. F., Allard, C., Menard, J., et al. (2012) Impact of the creation 
of a specialized clinic for prenatal blood sampling and follow-up care 
in pregnant women 
Study Question: What is the effect on gestational diabetes mellitus screening rates of 
having  a specialized clinic for pregnant women offering blood 
sampling and screening for GDM and what is the impact on perinatal 
outcome of having early GDM screening and follow-up provided by the 
specialized clinic? 
Source of Funding: Canadian Diabetes Association, Fonds de la recherche en santé du 
Québec, and the Canadian Institutes for Health  
Source Population: Women who delivered during a period when the BSP clinic was 
operating compared to those before the clinic was established. Women 
who had GDM screening in the first trimester with women who had 
screening during the second trimester and with women not screened 
Study Population: 2468 deliveries during the 2004-2005 period, 2591 from 2006-2007 and 
2780 from 2008-2009.  
Design: Retrospective cohort study 
Intervention: Specialized diabetes clinic, GDM screening in the first trimester 
(median = 9.9 gw [8.3-11.6]) 
Intervention Setting: Regional hospital  
Comparison: Women screened in the second trimester (median 27.0 gw [25.9-27.7]) 
and women not screened. 
Measurement: Diagnosis of GDM based on diagnostic codes in the summary discharge 
forms admitted for delivery. Clinical data available in electronic health 
records (results of testing not always included - only diagnosis). 
Different time frames may reflect differences in clinical practices 
outside of BSP clinic and early testing. Tried to control for this by 
comparing two time frames before the opening of the clinic. Historical 
control groups  
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Results: C-section rate increased over time but held stable after the clinic was 
established. No significant difference in duration of gestation, birth 
weight, macrosomia, and rates of fracture/dislocation between three 
periods. Maternal age and duration of gestation similar for early vs late 
vs no screening. GDM more often diagnosed in women screened during 
1st trimester. C-section higher in women who did not have GCT during 
pregnancy than those who had early screening. Offspring more likely to 
have complications if no screening than first trimester screen. Babies 
less likely to be admitted to NICU if early vs late screening and no 
screening. Median birth weight and macrosomia similar in three 
subgroups  
Attrition: NR 
Quality Score: Fair 
 
 
 
 
Study 9 
KQ1 
Hughes, R. C., Moore, M. P., Gullam, J. E., et al. (2014). An early 
pregnancy HbA1c>/=5.9% (41 mmol/mol) is optimal for detecting 
diabetes and identifies women at increased risk of adverse pregnancy 
outcomes 
Study Question: What is the optimal HbA1c threshold for detecting diabetes in early 
pregnancy as defined by an early OGTT at < 20 weeks and what 
pregnancy outcomes are related to this threshold? 
Source of Funding: Canterbury Medical Research Foundation, the New Zealand Society for 
the Study of Diabetes, the New Zealand National Lottery Grants Board, 
the Health Research Council of New Zealand, and the Diabetes 
Research and Training Trust of Christchurch, New Zealand 
Source Population: 16,122 women in Christchurch NZ between 2008-2010.  
Study Population: Subset of women who got a HbA1c measurement with their first 
antenatal bloods and completed an early OGTT. 4021 women invited 
for OGTT, 974 had OGTT before 20 weeks. Exclusion criteria: known 
preexisting diabetes, multiple gestation, pregnancy loss. 
Design: Prospective cohort study 
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Intervention: HbA1c at first antenatal blood draw; subset had early OGTT 
Intervention Setting: Primary care setting in Christchurch, New Zealand 
Comparison: 2-hr, 75-g OGTT or 50-g & 75-g OGTT at 24-28 weeks gestation 
Measurement: HbA1c measure at median 47 days. Used A1c ≥ 5.9% and < 6.5%. 75-g 
2-h OGTT performed before 20 weeks. WHO criteria applied 
retrospectively to define diabetes and GDM. Research assistants 
collecting data were blinded to both the HbA1c and OGTT results. 
Three labs involved in blood sampling - techs blinded to HbA1c. All 
labs used identical methods. Possible variation calculated at 0.02%. 
OGTT subject to preanalytical error d/t variation in sample handling 
and having reproducibility issues. HbA1c measurements more 
reproducible.  
Results: HbA1c cutoff ≥ 5.9%: 100% sens, 97.4% spec, 18.8% PPV. HbA1c < 
4.8% excluded early GDM. Women with A1c ≥ 5.9% compared with 
women with A1c < 5.9% had a greater than 2-fold increase RR of 
preeclampsia, shoulder dystocia, and major congenital anomaly; greater 
than 3-fold increase RR of perinatal death; greater than 1.5-fold 
increased RR of delivery before 37 weeks gestation. Higher risk of 
adverse pregnancy outcomes persisted even when those treated for 
GDM were included (except fetal death). 
Attrition: 3047 women invited to have OGTT did not complete 
Quality Score: Fair 
 
 
 
 
Study 10 
KQ1 
Most, O. L., Kim, J. H., Arslan, A. A., (2009). Maternal and neonatal 
outcomes in early glucose tolerance testing in an obstetric population 
in new you city. 
Study Question: How do pregnancy outcomes compare in women who were diagnosed 
with GDM early in pregnancy with those diagnosed at the standard 24-
28 weeks gestation? 
Source of Funding: NR 
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Source Population: 340 pregnant women evaluated 
Study Population: 340 women with GDM, in a singleton pregnancy coming from an inner 
city population in NY, NY from 2003 to 2007.  
Design: Retrospective cohort design 
Intervention: Women diagnosed early in pregnancy 
Intervention Setting: Inner city hospital 
Comparison: Women diagnosed at the standard 24-28 weeks.  
Measurement: All patients screened with GCT at first pregnant visit. Positive screen + 
OGTT ≥ 2 abnormal values diagnosed GDM. Normal results underwent 
testing at 24-28 weeks. Maternal and neonatal data obtained from 
computerized diabetic database: maternal age. ethnicity, BMI, parity, 
previous cesarean, gestational age at dx, and lab results from 
GCT/GTT. Maternal and neonatal outcomes (mode of delivery, 
gestational age at birth, metal birth wt, Apgars, preterm delivery, 
hypertensive disorders, shoulder dystocia, lacerations).  
Results: Early onset GDM: higher BMI, older, higher parity, no difference in 
race, more pharmacotx. Macrosomia and LGA higher in early GTT 
groups. Cesarean higher in early group (no differences in indications for 
section) more lacs (but less severe) preterm, Apgars, dystocia, 
hypertensive disorders not statistically significant.  
Attrition: No info on dropouts  
Quality Score: Fair/Good 
 
 
 
 
Study 11 
KQ1 
Scott, D. A., Loveman, E., McIntyre, L., & Waugh, N. (2002) 
Screening for gestational diabetes: A systematic review and economic 
evaluation 
Study Question: What is the current knowledge and what are research needs to assist 
with policy making in the interim, pending future research? 
Source of Funding: NHS R&D Health Technology Assessment (HTA) Programme  
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Source Population: All primary studies that investigated any method of screening for GDM 
were included. authors person reference collections, MEDLINE, 
EMBASE, and the Cochrane library. Citations of retrieved reference 
were also searched. Authors of studies reviewed were not contacted 
Study Population: Majority of studies were case series; number were quasi-experimental 
observational studies. No studies that evaluated the effects of 
antecedent diabetes, or studies that did not evaluate screening for GDM 
in some way. Only English language studies were identified. 
Unrestricted to study design. 
Design: Systematic Review 
Intervention: Tests and thresholds used for screening and diagnosis, incidence of 
GDM, sensitivity, specificity and positive predictive value (PPV) of the 
tests, country of study, time of testing and fasting status.  
Intervention Setting: National Institute for Clinical Excellence (NICE) 
Comparison: The GTT is regarded as the ‘gold standard’ for diagnosis of GDM  
Measurement: Data extracted included tests and thresholds used for screening and 
diagnosis, incidence of GDM, sensitivity, specificity, and positive 
predictive value of the tests, country of study, time of testing and 
fasting status. Risk factor screening, urine testing, various blood tests, 
and combinations thereof.  
Results: Different diagnostic tests and screening tests. Mostly observational 
studies, few incorporating control groups. Few studies have used an 
RCT design. Benefits reported in reduction of macrosomia not adverse 
outcomes. FPG values may not be relevant because postprandial values 
may be more closely linked with fetal weight gain. High diagnostic 
threshold should be used because low values are low risk. FPG <4.8 
mmol/L should exclude GDM. 
Attrition: N/A 
Quality Score: Good 
 
 
 
 
55 
Study 12 
KQ1 
Seshiah, V., Balaji, V., Balaji, M. S., et al. (2007) Glycemic level at the 
first visit and prediction of GDM 
Study Question: What glycemic level at first visit is likely to predict gestational diabetes 
mellitus? 
Source of Funding: World Diabetes Foundation (Denmark) 
Source Population: 4151 pregnant women attending the antenatal health posts across 
Chennai city 
Study Population: 739 consecutive women with GDM were enrolled irrespective of 
gestational weeks. Women with pre-gestational diabetes were excluded 
Design: Prospective cohort study 
Intervention: 2-hr, 75-g OGTT at first antenatal visit 
Intervention Setting: Community based study 
Comparison: 2-hr, 75-g OGTT at subsequent antenatal visits 
Measurement: Diagnosis made based on WHO criteria. Value of 140 mg/dL used as 
diagnosis of GDM. Retrospectively looked at glycemic index at the first 
visit of the 211 women who manifested GDM later. 120 mg/dL used as 
cut-off to determine predictive value of first visit OGTT because this 
level maximizes sensitivity and specificity in predicting macrosomia.  
Results: 2hrPG < 120 mg/dL. 56% of those who would go on to develop GDM 
had levels ≥ 120 mg/dL. 44% of those who would go on to develop 
GDM had levels < 120 mg/dL. Macrosomia occurs on a continuum with 
2hrPG. Irrespective of 2hrPG (≥ or < 120) at first visit, women may still 
develop GDM. No first visit glycemic level predicted GDM 
Attrition: Attrition not addressed 
Quality Score: Poor 
 
 
 
 
56 
Study 13 
KQ2 
Syed, M., Javed, H., Yakoob, M. Y., & Bhutta, Z. A. (2011) Effect of 
screening and management of diabetes during pregnancy on stillbirths 
Study Question: What is the potential impact of early detection and control of diabetes 
mellitus during pregnancy on stillbirths? 
Source of Funding: A grant to the US Fund for UNICEF from the Bill & Melinda Gates 
Foundation  
Source Population: Searched PubMed, Cochrane Database, WHO Regional Databases, 
hand search of bibliographies. Experts contacted 
Study Population: Developed and developing countries. Included populations not 
described. Irrespective of language. Articles included in meta-analysis 
irrespective of methodological quality. Exclusion criteria: Studies that 
did not report on relevant outcomes. Studies that did not focus on the 
selected intervention. 70 studies included (14 intervention, and 56 
observational) 
Design: Systematic review 
Intervention: Studies linking early screening, control, and detection of GDM and 
stillbirth 
Intervention Setting: The studies selected were from both developed and developing 
countries  
Comparison: Standard screening (glucose challenge test between 24th to 28th week 
of gestation  
Measurement: Meta-analysis for any outcome with more than one study. Visual 
inspection for statistical heterogeneity. An I2 value greater than 50% 
was taken to represent substantial and high heterogeneity. The CHERG 
adaptation of the GRADE criteria was applied to grade the evidence 
presented by the studies in our meta-analyses. For the intervention of 
diabetes screening and management, in general, during pregnancy, 
expert consensus was also sought via the Delphi method.  
Results: One study and one review unable to show early testing better than late 
in improving perinatal mortality. No difference in screening guidelines 
on stillbirth rates (ADA & WHO).  
Attrition: N/A 
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Quality Score: Good 
 
 
 
 
Study 14 
KQ1 
Zhu, W. W., Yang, H. X., Wei, Y. M., et al. (2013). Evaluation of the 
value of fasting plasma glucose in the first prenatal visit to diagnose 
gestational diabetes mellitus in china. 
Study Question: What is the value of fasting plasma glucose value in the first prenatal 
visit to diagnose GDM? 
Source of Funding: NR 
Source Population: 17,186 pregnant women who received care at the GDM centers at 13 
different hospitals in China.  
Study Population: 14,039 pregnant women with blood glucose test results linked to 
gestational week were available for analysis. Previously known diabetic 
patients were excluded 
Design: Retrospective cohort study 
Intervention: FPG at first prenatal visit 
Intervention Setting: GDM centers at 13 different hospitals in China 
Comparison: One step GDM screen (75-g) OGTT at 24-28 weeks gestation 
Measurement: FPG performed at first prenatal visit. 75-g OGTT at 24-28 week. 
Diagnosis according to the criteria established by MOH China. 
Results: Median first trimester FPG was 4.58 r 0.44 mmol/L; 17.5% of patients 
diagnosed with GDM. Incidence of GDM increased with every 0.50 
mmol/L increase in FPG. FPG values decreased throughout pregnancy. 
When the FPG cutoff at the first visit was 5.60 specificity was 0.99 (no 
sensitivity given). > 7 mmol/L considered diagnostic of previous 
undiagnosed diabetes. 6.10-6.99 mmol/L be treated as GDM. 5.10-6.09 
mmol/L nutrition and exercise advice.  
Attrition: No attrition 
Quality Score: Fair/Good 
 
